Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Type of study
Language
Publication year range
2.
Hum Immunol ; 63(2): 83-90, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11821155

ABSTRACT

HLA-G is selectively expressed in extravillous trophoblast of human placenta, which does not express classical HLA-A and -B molecules. Several studies report the role of HLA-G as a molecule involved in immune tolerance. By interacting with NK and T cells inhibitory receptors, HLA-G may downregulate their cytotoxicity functions. To appreciate the biologic and clinical relevance of HLA-G expression in lung diseases, HLA class I and HLA-G expression were analyzed in a panel of 36 ex vivo neoplastic tissues and 8 non-neoplastic lung tissues. Immunohistochemical analysis was performed using a pan-HLA class I antibody (W6/32) and three different specific anti-HLA-G antibodies (87G, MEMG/9 and 4H84). These findings demonstrated that HLA-G products were not expressed in pulmonary structural cells. However, HLA-G molecules were detected in activated macrophages and dendritic cells infiltrating lung carcinomas (33%) and nontumoral pulmonary diseases (25%). HLA-G expression was not correlated with classical HLA alterations. No statistical correlation was found between HLA-G expression and clinical or biologic parameters except high tumor size. The expression of HLA-G in myelo-monocytic cells infiltrating lung pathologic tissues could alter antigenic presentation and contribute to decrease immune response efficiency, subsequently favoring the progression of tumoral or inflammatory processes.


Subject(s)
Dendritic Cells/metabolism , Lung Diseases/metabolism , Lung/metabolism , Macrophages/metabolism , Female , HLA Antigens/metabolism , HLA-G Antigens , Histocompatibility Antigens Class I/metabolism , Humans , Lung/cytology , Lung Neoplasms/metabolism , Male
3.
J Immunol ; 164(12): 6426-34, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10843698

ABSTRACT

After infection, human CMV (HCMV) establishes a latent and persistent infection in immature myeloid progenitors and peripheral blood monocytes. Completion of the HCMV life cycle is possible upon maturation of monocytes to tissue macrophages and under permissive circumstances, e.g., immunosuppression. We investigated the hypothesis that HLA-G molecules could be induced during HCMV reactivation in activated macrophages to favor virus dissemination. In this study, we provide evidence that HLA-G Ags are produced during viral reactivation in macrophages generated after allogeneic stimulation of HCMV latently infected monocytes. While HLA-G surface expression is up-regulated, classical MHC-I molecules are partially down-regulated by HCMV. In vivo, bronchoalveolar macrophages collected from patients suffering from acute HCMV pneumonitis also express HLA-G molecules. The direct correlation between HLA-G Ag induction and HCMV infection was confirmed in U-373 MG astrocytoma cells. Soluble HLA-G expression is stimulated upon HCMV infection, and this modulation depends on the cooperative action of the two immediate-early-1 pp72 and immediate-early-2 pp86 products. Because HLA-G transcription is active in macrophages and U-373 MG astrocytoma cells, it is likely that the modulation of HLA-G protein expression during HCMV replication occurs at a post-transcriptional level. Our data suggest that induction of HLA-G molecules could be an additional mechanism that helps HCMV to subvert host defenses.


Subject(s)
Cytomegalovirus/immunology , HLA Antigens/biosynthesis , Histocompatibility Antigens Class I/biosynthesis , Macrophage Activation , Macrophages/immunology , Macrophages/virology , Astrocytoma/immunology , Astrocytoma/metabolism , Cell Line , Cytomegalovirus Infections/immunology , Cytomegalovirus Infections/metabolism , HLA Antigens/metabolism , HLA-G Antigens , Histocompatibility Antigens Class I/metabolism , Humans , Isoantigens/immunology , Macrophages/metabolism , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Macrophages, Alveolar/virology , Monocytes/immunology , Monocytes/metabolism , Monocytes/virology , Pneumonia, Viral/immunology , Pneumonia, Viral/metabolism , Tumor Cells, Cultured , Virus Latency/immunology
4.
Hum Immunol ; 61(11): 1086-94, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11137211

ABSTRACT

As trophoblast cells and macrophages share cellular characteristics, we investigated the expression of HLA-G antigens during the myelomonocytic differentiation. Analyses with the 87G and 16G1 monoclonal antibodies demonstrated that HLA-G was not expressed in peripheral blood monocytes, in in vitro differentiated dendritic cells and macrophages, and in resident mononuclear phagocytes infiltrating healthy tissues. Conversely, activated macrophages and dendritic cells localized in tumoral biopsies of some lung carcinomas expressed HLA-G antigens. Induction of HLA-G expression at the cell surface of the monohistiocytic cell line U 937 with different cytokines strongly suggests that cytokines secreted during inflammation may be involved in this specific upregulation. Bronchoalveolar macrophages collected from patients suffering from acute HCMV pneumonitis also expressed HLA-G molecules. In vitro, we thus demonstrated that HLA-G antigens are produced during viral reactivation in the macrophages generated after allogeneic stimulation of HCMV latently infected monocytes. Our data suggest that inflammatory processes in lung tissues, like tumoral transformation and HCMV acute infection, are likely to induce HLA-G molecules in infiltrating macrophages and dendritic cells. The expression of molecules capable of downregulating both the innate and adoptive immunity could be a mechanism that helps tumoral and HCMV infected cells to escape immune response.


Subject(s)
Dendritic Cells/immunology , HLA Antigens/biosynthesis , Histocompatibility Antigens Class I/biosynthesis , Macrophages/immunology , Monocytes/immunology , Acute Disease , Biopsy , Carcinoma/immunology , Carcinoma/pathology , Cell Line , Cytokines/pharmacology , Flow Cytometry , HLA Antigens/immunology , HLA-G Antigens , Histocompatibility Antigens Class I/immunology , Humans , Lung/immunology , Lung/pathology , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Macrophage Activation , Macrophages/drug effects , Monocytes/drug effects , Monocytes/virology , Pneumonia, Viral/immunology , U937 Cells
5.
Life Sci ; 64(15): 1329-37, 1999.
Article in English | MEDLINE | ID: mdl-10227589

ABSTRACT

After intravenous injection, the main part of nanoparticles trapped by the spleen are concentrated in the marginal zone. The first step of this capture is the adhesion of the particles to the marginal zone macrophages. As classical techniques of cell suspension preparation did not allow to isolate without damage these actively capturing cells, tightly bound to a well-developed reticular meshwork, we designed a tissue slice incubation method, in order to study in vitro the interaction of nanoparticles with these particular macrophages, in conditions close to in vivo. In a serum supplemented medium, this in vitro model was able to give similar uptake profile than after intravenous injection of nanoparticles thus proving its validity. Surprisingly, no significant decrease of nanoparticles capture was observed when the medium was depleted from complement, immunoglobulins or proteins affine for heparin, while substitution of serum by purified albumin allowed a near optimal uptake. Addition of competitive ligands for lectin-like receptors did not show any clear inhibition of spleen capture. On the other hand, the scavenger receptor blocking agents, such as maleylated albumin or polyinosinic acid, induced a strong reduction of the spleen nanoparticles uptake. Thus, this paper proposes an in vitro binding assay as a reliable method to investigate the spleen capture of a large variety of nanoparticulate drug carriers. It is also a useful methodology to highlight the interactions between spleen cells and nanoparticles. The data obtained suggest that capture of nanoparticles depends on a multifactorial and complex phenomenon involving for a part albumin and the scavenger receptor.


Subject(s)
Blood Proteins/metabolism , Membrane Proteins , Receptors, Lipoprotein , Spleen/cytology , Spleen/metabolism , Animals , Cell Adhesion , Culture Media , Macrophages/physiology , Mice , Organ Culture Techniques , Particle Size , Polystyrenes , Receptors, Immunologic/metabolism , Receptors, Scavenger , Scavenger Receptors, Class B , Serum Albumin, Bovine/metabolism
6.
Tissue Antigens ; 53(4 Pt 1): 335-46, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10323337

ABSTRACT

To evaluate the biological relevance of HLA-G expression during tumoral transformation, we analyzed its expression in different malignant cells and immune effector cells infiltrating solid tumors. Our analysis of 33 tumor cell lines and 53 tumoral biopsies demonstrated that: i) six tumor cell lines display HLA-G transcription with differential alternative splicing patterns and only Jeg3 choriocarcinoma and MCF-7 breast adenocarcinoma cell lines express HLA-G translated products; and ii) HLA-G antigens are not expressed in malignantly transformed cells derived from lung (n=18), liver (n=5), colon (n=5), breast (n=10), kidney (n=5), ovary (n=5), and larynx (n=5) tissues ex vivo. The healthy tissues surrounding these tumor tissues do not express HLA-G molecules either. On the other hand, surprisingly, HLA-G products were detected in activated macrophages and dendritic cells localized in tumoral biopsies of 5 out of 18 different lung carcinomas. No HLA-G labelling was observed in resident mononuclear phagocytes of surrounding healthy tissues. Our observations clearly demonstrate that HLA-G is not a marker of malignant cells but appears as a gene expressed in tumor-associated macrophages and dendritic cells, preferentially in those recruited in lung carcinomas. Our findings suggest that specific environmental factors around lung tumors could be involved in the induction of HLA-G protein expression.


Subject(s)
Cell Transformation, Neoplastic/immunology , HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Neoplasms/immunology , Cell Movement/immunology , Dendritic Cells/immunology , Dendritic Cells/pathology , Female , Flow Cytometry , HLA Antigens/biosynthesis , HLA-G Antigens , Histocompatibility Antigens Class I/biosynthesis , Humans , Immunohistochemistry , Macrophage Activation/immunology , Macrophages/immunology , Macrophages/pathology , Male , Neoplasms/pathology
7.
Pharm Res ; 16(1): 37-41, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9950276

ABSTRACT

PURPOSE: To investigate the influence of animal species and nanoparticle surface characteristics on the intrasplenic distribution of polystyrene nanoparticles. METHODS: Two types of fluorescent polystyrene nanoparticles (Estapor and Fluoresbrite), plain or coated, were used in mice and rats. First, a fluorimetric method was developed for nanoparticle tissue quantification. Then, intrasplenic distribution of plain or coated nanoparticles was studied using histological examination and image analysis. Finally, the role of direct interactions between nanoparticles and spleen capturing cells was assessed by in vitro binding assays, using incubation of thick spleen slices with polystyrene nanoparticles. RESULTS: The two types of polystyrene nanoparticles showed different levels of trapping: Fluoresbrite nanoparticles were more efficiently trapped by the spleen than Estapor nanoparticles, both in mice and rats. In mice, most of the injected nanoparticles were localized in the marginal zone of the spleen, involving a special population of capturing cells, while in rats, the predominant capture occured in the red pulp. In mice, coated nanoparticles were localized both in the marginal zone and in the red pulp, whereas the coating did not seem to change the intrasplenic distribution of the nanoparticles in rats. CONCLUSIONS: These complementary approaches showed different uptake pathways of nanoparticles, according to their surface characteristics and the rodent species used.


Subject(s)
Spleen/metabolism , Animals , Ethylenediamines/pharmacology , Fluorometry , Mice , Microchemistry , Particle Size , Poloxamer/pharmacology , Polyethylene Glycols/pharmacology , Rats , Solubility , Species Specificity , Surface Properties , Surface-Active Agents/pharmacology , Water/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...